Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPETradingView·Sep 3 at 10:13 AMPASG+0.21%
Passage Bio announces $70 million private placement at $1.39 per share, including pre-funded warrantsPUBT·Sep 3 at 10:03 AMPASG+0.21%
Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q SummaryTradingView·Aug 10 at 11:21 AMPASG+0.21%
13:41 ET$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASGprnewswire·Jul 23 at 05:41 PMPASG+0.21%SLP0.00%
Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% StakeTradingView·Jul 3 at 01:26 AMPASG+0.21%
Lynx1 Capital Management LP buys $206,064 of Passage Bio common sharesPUBT·Jun 29 at 08:31 PMPASG+0.21%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jun 25 at 05:05 PMNNOX+2.23%ATLN0.00%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Jun 25 at 12:05 PMTELA-4.00%PASG+0.21%
9 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jun 24 at 09:05 PMSPRY-0.24%TSHA-0.20%
Passage Bio shares are trading higher after the company announced it entered into a definitive merger agreement with Remix Therapeutics.benzinga_article·Jun 24 at 08:43 PMPASG+0.21%
Passage Bio agrees to merge with Remix Therapeutics in all-stock dealPUBT·Jun 24 at 08:06 PMPASG+0.21%
